Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Osteoporosis International

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01623686PMID 9166391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of 3-year treatment with ipriflavone on peripheral bone mass in postmenopausal women

  2006cited by this paper
• Ipriflavone inhibits bone resorption in rats: Effect of experimental conditions

  2006cited by this paper
• Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone

  2005cited by this paper
• Ipriflavone does not alter bone apatite crystal structure in adult male rats

  1996cited by this paper
• Ipriflavone improves bone density and biomechanical properties of adult male rat bones

  1995cited by this paper
• Evaluation of therapeutic efficacy in osteoporosis

  1995cited by this paper
• Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study

  1994cited by this paper
• Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years.

  1994cited by this paper
• Nasal salmon calcitonin in osteoporosis

  1994cited by this paper
• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report

  1994cited by this paper
• Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.

  1994cited by this paper
• Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.

  1994influential reference
• A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis

  1994influential reference
• Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass

  1994cited by this paper
• Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause

  1994cited by this paper
• Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites

  1994cited by this paper
• Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women

  1993cited by this paper
• Long‐term fracture prediction by bone mineral assessed at different skeletal sites

  1993cited by this paper
• Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.

  1993cited by this paper
• A clinical trial on the effects of a combination of elcatonin (Carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women

  1993cited by this paper
• Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

  1993cited by this paper
• Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.

  1992cited by this paper
• Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis

  1992cited by this paper
• Short-term treatment of Paget's disease of bone with ipriflavone.

  1992cited by this paper
• Do estrogens improve bone mineral density in osteoporotic women over age 65?

  1992cited by this paper
• Lack of any estrogenic effect of ipriflavone in postmenopausal women

  1992cited by this paper
• Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

  1992cited by this paper
• The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials

  1991cited by this paper
• Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line

  1991cited by this paper
• A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women

  1991cited by this paper
• Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.

  1991cited by this paper
• Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

  1990cited by this paper
• Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

  1990cited by this paper
• Analysis of serial measurements in medical research.

  1990cited by this paper
• Analysis of serial measurements in medical research.

  1990cited by this paper
• A model of vertebral trabecular bone architecture and its mechanical properties.

  1990cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.

  1986cited by this paper
• Effect of ipriflavone on the response of uterus and thyroid to estrogen.

  1986cited by this paper
• THE DIAGNOSTIC VALIDITY OF LOCAL AND TOTAL BONE MINERAL MEASUREMENTS IN POSTMENOPAUSAL OSTEOPOROSIS AND OSTEOARTHRITIS

  1986cited by this paper
• Prevention of spinal osteoporosis in oophorectomised women.

  1980cited by this paper
• Effect of estrogens and calcium carbonate on bone loss in postmenopausal women.

  1977cited by this paper

• Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Neglected bone health needs more care

  2022cites this paper
• Preparation of chitosan/sodium lignosulfonate/Ag NPs: A potent and green bio-nanocomposite for the treatment of glucocorticoid induced osteoporosis in rats

  2022cites this paper
• The Efficacy and Safety of Ipriflavone in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and Meta-analysis.

  2020cites this paper
• Ipriflavone in the Treatment of Postmenopausal Osteoporosis

  2017cites this paper
• Beneficial Effects of a Flavonoid Fraction of Herba Epimedii on Bone Metabolism in Ovariectomized Rats

  2016cites this paper
• Are Soy-Milk Products Viable Alternatives to Cow’s Milk?

  2016cites this paper
• Antimutagenic activity of ipriflavone against the DNA-damage induced by cyclophosphamide in mice.

  2014cites this paper
• Management of postmenopausal osteoporosis and the prevention of fractures.

  2014cites this paper
• Polifenoles del vino tinto inhiben la proliferación, e inducen apoptosis en células de cáncer de próstata LNCaP

  2012cites this paper
• Scottish Intercollegiate Guidelines Network

  2010cites this paper
• Women's health: selected topics.

  2010cites this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cites this paper
• Anabolics in osteoporosis: the emerging therapeutic tool.

  2010cites this paper
• The future of ipriflavone in the management of osteoporotic syndromes

  2009cites this paper
• Icariin Flavonoid in Horny Goat Weed Boosts Bone Density in Postmenopausal Women

  2009cites this paper
• Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies.

  2009cites this paper
• Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

  2009cites this paper
• Design for an ipriflavone multicenter European fracture study

  2009cites this paper
• Calcio e derivati della vitamina D, terapia sostitutiva, calcitonina, fluoruri, bisfosfonati

  2009cites this paper
• Effect of Ipriflavone on Osteoblasts and Osteoclasts during Guided Bone Augmentation

  2007cites this paper
• Complementary and alternative medicine use and the menopausal transition : the effect of a Chinese herbal formula on vasomotor symptoms and bone turnover

  2007cites this paper
• Effects of ipriflavone on augmented bone using a guided bone regeneration procedure.

  2007cites this paper
• Calcium from LactoCalciumTM Milk Mineral after Digestion with Pepsin Stimulates Mineralized Bone Nodule Formation in Human Osteoblast-Like SaOS-2 Cells in Vitro and May Be Rendered Bioavailable in Vivo

  2007cites this paper
• Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

  2006cites this paper
• Identification of Isoflavonoid Metabolites in Humans

  2006cites this paper
• Ipriflavone modulates IGF‐I but is unable to restore bone in rats

  2005influential citation
• Nutritional Strategies in the Prevention of Osteoporosis : A Summary

  2004cites this paper
• Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

  2004cites this paper
• Bone mineral density thresholds for pharmacological intervention to prevent fractures.

  2004cites this paper
• FITOESTROGÊNIOS: VALOR TERAPÊUTICO NO CLIMATÉRIO PHYTOESTROGENS: THERAPEUTIC VALUE IN CLIMACTERIC

  2004cites this paper
• The Effects of Age, Disease, Procedures, and Drugs on Bone Density

  2004cites this paper
• Current approaches to the prevention and treatment of postmenopausal osteoporosis.

  2003cites this paper
• Novel therapies for osteoporosis

  2003cites this paper
• A Comparison of Bone Mass Measurements of Vegetarians and Omnivores

  2003cites this paper
• Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'ostéoporose au Canada

  2003cites this paper
• Novel therapeutic options for osteoporosis

  2002cites this paper
• Estrógenvirk efni í plöntum og áhrif þeirra á heilsu manna

  2002cites this paper
• Use of alternative and complementary medicine in menopause

  2002cites this paper
• Soy Intake Related to Menopausal Symptoms, Serum Lipids, and Bone Mineral Density in Postmenopausal Japanese Women

  2001cites this paper
• Clinical Effects of Phytoestrogens

  2001cites this paper
• Cross-species and interassay comparisons of phytoestrogen action.

  2001cites this paper
• A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy.

  2001cites this paper
• Efficacy of ipriflavone in preventing adverse effects of leuprolide.

  2001cites this paper
• Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.

  2001cites this paper
• Phytoestrogens and healthy aging: gaps in knowledge: A workshop report

  2001cites this paper
• Phytoestrogens as hormone replacement therapy: an evidence-based approach.

  2000cites this paper
• Alternative therapies for menopause.

  2000cites this paper
• Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women.

  2000cites this paper
• Drug-Induced Lymphopenia

  1999cites this paper
• Phytoestrogens and menopause.

  1999cites this paper
• Responsiveness of endpoints in osteoporosis clinical trials--an update.

  1999cites this paper
• Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

  1999cites this paper
• Phyto-oestrogen excretion and rate of bone loss in postmenopausal women

  1998cites this paper
• Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence.

  1998cites this paper
• Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.

  1997cites this paper
• Evaluation of the Efficacy and Safety of Reosto in Postmenopausal Osteoporosis : A Prospective , Randomized , Placebo-Controlled , Double Blind , Phase III Clinical Trial

  year unknowninfluential citation
• Evaluation of efficacy and safety of Menosan in the management of postmenopausal syndrome : A prospective , randomized , double blind , placebo-controlled , phase III clinical trial

  year unknowncites this paper